An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 11, 2014, Pages 2528-2542

  Hale, Andrew ^a   Lee, Changjin ^b   Annis, Sofia ^a   Min, Pil Ki ^a,c   Pande, Reena ^a   Creager, Mark A ^a   Julian, Colleen G ^d   Moore, Lorna G ^d   Mitsialis, S Alex ^b   Hwang, Sarah J ^a   Kourembanas, Stella ^b   Chan, Stephen Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Circulating microRNA; Endothelial; Hypoxamir; Hypoxia; Mitochondrial metabolism

Indexed keywords

ARGONAUTE 2 PROTEIN; MICRORNA 16; MICRORNA 21; MICRORNA 210; MICRORNA 223; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ADAPTATION; ANIMAL CELL; ARTICLE; CASE CONTROL STUDY; CELL COMMUNICATION; CELL HYPOXIA; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOPRECIPITATION; INTERMITTENT CLAUDICATION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; NORMAL HUMAN; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; REOXYGENATION; ULTRACENTRIFUGATION; UPREGULATION;

EID: 84905371367     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.06.012     Document Type: Article

References (58)

1. Tapuria N., Kumar Y., Habib M.M., Abu Amara M., Seifalian A.M., Davidson B.R. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury-a review. J. Surg. Res. 2008, 150:304-330.
2. Kloner R.A. Clinical application of remote ischemic preconditioning. Circulation 2009, 119:776-778.
3. Bolte C.S., Liao S., Gross G.J., Schultz Jel J. Remote preconditioning-endocrine factors in organ protection against ischemic injury. Endocr. Metab. Immune Disord. Drug Targets 2007, 7:167-175.
4. Kant R., Diwan V., Jaggi A.S., Singh N., Singh D. Remote renal preconditioning-induced cardioprotection: a key role of hypoxia inducible factor-prolyl 4-hydroxylases. Mol. Cell. Biochem. 2008, 312:25-31.
5. Cai Z., Luo W., Zhan H., Semenza G.L. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17462-17467.
6. Albrecht M., Zitta K., Bein B., Wennemuth G., Broch O., Renner J., et al. Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. Basic Res. Cardiol. 2013, 108:314.
7. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009, 10:273-284.
8. Chen Z., Li Y., Zhang H., Huang P., Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010, 29:4362-4368.
9. Puissegur M.P., Mazure N.M., Bertero T., Pradelli L., Grosso S., Robbe-Sermesant K., et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2010, 18:465-478.
10. Semenza G. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem. J. 2007, 405:1-9.
11. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
12. Laterza O.F., Lim L., Garrett-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 2009, 55:1977-1983.
13. Heneghan H.M., Miller N., Kerin M.J. MiRNAs as biomarkers and therapeutic targets in cancer. Curr. Opin. Pharmacol. 2010, 10:543-550.
14. Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010, 107:677-684.
15. Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3:109-113.
16. Wulfken L.M., Moritz R., Ohlmann C., Holdenrieder S., Jung V., Becker F., et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6:e25787.
17. Zhao A., Li G., Peoc'h M., Genin C., Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2013, 94:115-120.
18. Jung E.J., Santarpia L., Kim J., Esteva F.J., Moretti E., Buzdar A.U., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118:2603-2614.
19. Madhavan D., Zucknick M., Wallwiener M., Cuk K., Modugno C., Scharpff M., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18:5972-5982.
20. Gunel T., Zeybek Y.G., Akcakaya P., Kalelioglu I., Benian A., Ermis H., et al. Serum microRNA expression in pregnancies with preeclampsia. Genet. Mol. Res. 2011, 10:4034-4040.
21. Zeng L., Liu J., Wang Y., Wang L., Weng S., Tang Y., et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front. Biosci. (Elite Ed.) 2011, 3:1265-1272.
22. Zeng L., Liu J., Wang Y., Wang L., Weng S., Chen S., et al. Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur. Neurol. 2012, 69:68-75.
23. Zhang Q., Kandic I., Faughnan M.E., Kutryk M.J. Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker. Biomarkers 2013, 18:23-29.
24. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
25. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
26. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
27. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 2010, 39:133-144.
28. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
29. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6328-6333.
30. Mittelbrunn M., Gutierrez-Vazquez C., Villarroya-Beltri C., Gonzalez S., Sanchez-Cabo F., Gonzalez M.A., et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2011, 2:282.
31. Hergenreider E., Heydt S., Treguer K., Boettger T., Horrevoets A.J., Zeiher A.M., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell Biol. 2012, 14:249-256.
32. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Guan Y., et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31:3513-3523.
33. Mok Y., Schwierzeck V., Thomas D.C., et al. MiR-210 is induced by Oct-2, regulates B cells, and inhibits autoantibody production. J. Immunol. 2013, 191:3037-3048.
34. Wilson M.J., Lopez M., Vargas M., Julian C., Tellez W., Rodriguez A., et al. Greater uterine artery blood flow during pregnancy in multigenerational (Andean) than shorter-term (European) high-altitude residents. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R1313-R1324.
35. Julian C.G., Wilson M.J., Lopez M., Yamashiro H., Tellez W., Rodriguez A., et al. Augmented uterine artery blood flow and oxygen delivery protect Andeans from altitude-associated reductions in fetal growth. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1564-R1575.
36. Lee C., Mitsialis S.A., Aslam M., Vitali S.H., Vergadi E., Konstantinou G., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126:2601-2611.
37. Parikh V.N., Jin R.C., Rabello S., Gulbahce N., White K., Hale A., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125:1520-1532.
38. King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12:421.
39. Kosaka N., Iguchi H., Hagiwara K., Yoshioka Y., Takeshita F., Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J. Biol. Chem. 2013, 288:10849-10859.
40. Tadokoro H., Umezu T., Ohyashiki K., Hirano T., Ohyashiki J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288:34343-34351.
41. Laffont B., Corduan A., Ple H., Duchez A.C., Cloutier N., Boilard E., et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013, 122:253-261.
42. Qi H.H., Ongusaha P.P., Myllyharju J., Cheng D., Pakkanen O., Shi Y., et al. Prolyl 4-hydroxylation regulates Argonaute 2 stability. Nature 2008, 455:421-424.
43. Wu C., So J., Davis-Dusenbery B.N., Qi H.H., Bloch D.B., Shi Y., et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol. Cell Biol. 2011, 31:4760-4774.
44. Giannakakis A., Sandaltzopoulos R., Greshock J., Liang S., Huang J., Hasegawa K., et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7:255-264.
45. Shen J., Xia W., Khotskaya Y.B., Huo L., Nakanishi K., Lim S.O., et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013, 497:383-387.
46. Kulshreshtha R., Ferracin M., Wojcik S., Garzon R., Alder H., Agosto-Perez F., et al. A microRNA signature of hypoxia. Mol. Cell Biol. 2007, 27:1859-1867.
47. Brown B.D., Gentner B., Cantore A., Colleoni S., Amendola M., Zingale A., et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 2007, 25:1457-1467.
48. Chan S.Y., Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010, 9:1072-1083.
49. Villarroya-Beltri C., Gutierrez-Vazquez C., Sanchez-Cabo F., Perez-Hernandez D., Vazquez J., Martin-Cofreces N., et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 2013, 4:2980.
50. Zhao D.S., Chen Y., Jiang H., Lu J.P., Zhang G., Geng J., et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc. Pathol. 2013, 22:444-450.
51. Endo K., Naito Y., Ji X., Nakanishi M., Noguchi T., Goto Y., et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol. Pharm. Bull. 2013, 36:48-54.
52. D'Alessandra Y., Devanna P., Limana F., Straino S., Di Carlo A., Brambilla P.G., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 2010, 31:2765-2773.
53. Li T., Cao H., Zhuang J., Wan J., Guan M., Yu B., et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin. Chim. Acta 2011, 412:66-70.
54. Lorenzen J.M., Volkmann I., Fiedler J., Schmidt M., Scheffner I., Haller H., et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am. J. Transplant. 2011, 11:2221-2227.
55. Wang L., Oka N., Tropak M., Callahan J., Lee J., Wilson G., et al. Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 2008, 136:335-342.
56. Leung C.H., Wang L., Nielsen J.M., Tropak M.B., Fu Y.Y., Kato H., et al. Remote cardioprotection by transfer of coronary effluent from ischemic preconditioned rabbit heart preserves mitochondrial integrity and function via adenosine receptor activation. Cardiovasc. Drugs Ther. 2014, 28:7-17.
57. Slagsvold K.H., Rognmo O., Hoydal M.A., Wisloff U., Wahba A. Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. Circ. Res. 2014, 114:851-859.
58. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12:861-874.